Shots:
- SanegeneBio has entered into a global licensing agreement with Genentech (Roche) to advance one of its RNAi programs, using SanegeneBio’s RNAi platform
- As per the deal, Genentech will receive exclusive worldwide rights to develop & commercialize the program, with SanegeneBio handling early development activities, after which Genentech will lead subsequent development & commercialization effortsÂ
- Under the terms, SanegeneBio will receive $200M upfront & ~1.5B in development & commercial milestones as well as tiered royalties
Ref: PRnewswire |  Image: Genentech & SanegeneBio | Press Release
Related News: Genentech (Roche) Reports Interim P-III (lidERA Breast Cancer) Trial Data on Giredestrant for Early Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
